Workshop on New Textile Schemes held in Bengaluru (See 'Corp Brief') IPR - Claim for injunction on the ground of breach of confidentiality cannot succeed if plaintiff fails to establish an enforceable confidentiality obligation and has himself publicly disclosed the relevant work: HC (See 'Legal Desk') Farmers need trust and simpler Systems, Not Just Credit: Chouhan (See 'Corp Brief') India's civilisational openness key to future leadership: William Dalrymple (See 'Corp Brief') A&C - Even if arbitration clause expressly names particular official as party-appointed arbitrator, such appointment cannot be sustained if that person is rendered ineligible u/s 12(5) read with Seventh Schedule: HC (See 'Legal Desk') NFRA Circular 2026- lessons to auditor on communication (See CORP EINSICHT) India-ROK Framework for Partnership in Shipbuilding, Shipping and Maritime Logistics (See 'Corp Brief') Food Business Startup Enabler Programme 2.0 conducted (See 'Corp Brief') Policy Support, Startups and Industry participation accelerate Circular Economy Transition (See 'Corp Brief' CCI okays restructuring by Vishakha Renewables and merger with Vishakha Glass (See 'Corp Brief') Scindia highlights historic 16% revenue growth of Department of Posts (See 'Corp Brief') IPR - Scope & clarity of invention are to be ascertained not just from independent claim in isolation, but by reading it together with dependent claims and accompanying drawings: HC (See 'Legal Desk') Samriddh Gram Initiative of India Nominated for WSIS Prizes 2026 (See 'Corp Brief') DARPG to observe 18th Civil Services Day on April 21, 2026 (See 'Corp Brief') IPR - Amended claims that significantly alter original claims transitioning from composition to non-native pancreatic ß cell must be duly considered by Controller independently without being influenced from prior conclusions - YES: HC (See 'Legal Desk') States showcase Best Practices in Digital Health at NHA Chintan Shivir (See 'Corp Brief') PMLA - Cricket betting involves cheating, which constitutes predicate offence under Prevention of Money Laundering Act, 2002, when FIR is registered for scheduled offences such as Section 420 IPC: SAFEMA (See 'Legal Desk') Chouhan reviews Kharif preparedness (See 'Corp Brief') CAQM reviews enforcement actions across NCR (See 'Corp Brief') PMLA - If actual tainted property or proceeds of crime are not traceable or available, authorities are empowered to attach alternative attachable property or untainted property of person involved: SAFEMA (See 'Legal Desk') Corporate laws (Amendment) Bill 2026 - Proposals affecting auditors (See CORP EINSICHT)

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.